Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-758-7 | CAS number: 87-62-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute Oral toxicity
Rat: LD50 = 1270 (940-2140) mg/kg bw (females, Montgomery et al. 1982)
LD50 = 1160 (830-1630) mg/kg bw (females, Montgomery et al. 1982)
LD50 = 1310 mg/kg bw (males, Montgomery et al. 1982)
LD50 = 840 (640-1120) mg/kg bw (males, Jacobson 1972)
LD50 = 1230 (890-1700) mg/kg bw (males, Vernot et al. 1977)
LD50 = 2040 mg/kg bw (Lindstrom et al. 1969)
LD50 = 300-2000 mg/kg bw (female, JECD, Val. 4)
Mouse: LD50 = 1160 (790-1710) mg/kg bw (males/females, Montgomery et al. 1982)
Acute Inhalation toxicity
Rat: IHT: 7h: LC50 >0.75 mg/l air, no mortality in a saturated vapour atmosphere (BASF 1982)
Acute Dermal toxicity
No studies or results are available.
Key value for chemical safety assessment
Additional information
There are only limited valid data available for the assessment of the acute toxicity of 2,6-xylidine.
Oral
Data an acute toxicity from various studies are listed in the section above. An acute toxicity study comparable to OECD guideline 401, groups of 10 male and 10 female rats were exposed to doses up to 5000 mg/kg bw. The only observed clinical signs of toxicity were slightly reduced behavioural state and signs of eye irritation. All animals survived doses up to 680 mg/kg bw (females) and 1000 mg/kg bw (males). Necropsy findings included signs of organ toxicity in livers, kidneys and lungs (Montgomery et al. 1982). Clinical symptoms and signs of toxicity observed by other investigators included mainly cyanosis (bluish coloration of lower limbs and of mouth and nose) (Jacobson et al.) and signs of methaemoglobinemia.
Inhalation
In an inhalation hazard test) 6 rats were exposed to a saturated vapour of 2,6-xylidine (0.75 mg/l air). At this concentration clinical signs observed included salivation, aqueous eye secretion and muzzles wiping during the exposure and salivation, apathy, closed eyes and slight secretion of the nose up to several hours after exposure; all effects reversible within 1day. Mortalities did not occur and no pathological abnormalities were detected in post mortem necropsy (BASF AG).
Dermal
Up to date there is no information available concerning the acute dermal toxicity of 2,6-xylidine.
In general, available data for 2,6-xylidine show a wide range of observed acute oral toxicity with LD50 values ranging from about 600 to 2000 mg/kg bw involving liver, lung and kidneys as the target sites of acute toxicity. Whether interlaboratory or individual variations among the different rat strains are responsible for the great variety of acute LD50 remains elusive.
As an aromatic amine 2,6-xylidine is able to form methemoglobinemia. The limit dose of 200 mg/kg caused moderate MetHb (approx.30%) after 4 hours. Thus, also with respect to the methemoglobinemia-forming potential "harmful" is the appropriate classification. There are no LC50 determinations; yet from an inhalation hazard test with no deaths in highly enriched or saturated vapor atmosphere the risk of inhaling high vapor concentrations seems
to be low.
Justification for classification or non-classification
Based on the criteria laid down in the GHS and considering the different results of the individual studies the test substance has to be classified in category 4 for oral exposure. Since an inhalation hazard test with rats exposed to 0.75 mg/l air for 7 hours did not result in any mortalities and only transient clinical signs or signs of respiratory irritation, there is no indication given to classify the substance according to EU or GHS requirements for its acute inhalative toxicity. For dermal exposure there is no reliable information available to classify the test substance according to the criteria laid down by the EU or GHS.
In addition the test substance is listed in the CLP Regulation No 1272-2008 on classification, labelling and packaging CLP of substances and mixtures and classified as acute toxic by oral, dermal and inhalative exposure (GHS cat. 4).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.